Corporate Banner
Satellite Banner
Automation & Microfluidics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Promethera Bio, EMD Millipore to Develop a Liver Pharmaco-Toxicological Assay

Published: Tuesday, March 11, 2014
Last Updated: Tuesday, March 11, 2014
Bookmark and Share
Companies collaborate to develop an improved ready-to-use microfluidic perfusion liver assay.

This new product is designed to perform more robust studies in pre-clinical toxicity and drug metabolism. Early availability of reliable human liver-based assays is critical to the pharmaceutical industry when deciding to bring a lead compound in clinical phase development. 

With their combined expertise and synergies, the companies are well positioned to develop a ready-to-use long-term liver-based assay. The Promethera Biosciences team is specialized in isolating, expanding and characterizing human liver progenitor cells for both cell therapy and liver cell based assays. EMD Millipore is a global life science company with an extensive portfolio of cell analysis instruments, research reagents and assays, cell culture and sample preparation products, plus advanced microfluidic cell culture as well as drug discovery services. 

Promethera Biosciences has identified a novel adult human hepatic progenitor cell population that can be maintained in vitro in two-dimensional and three-dimensional cell culture conditions providing new models for testing in vitro drug metabolism: Promethera H2Screen and H3screen. This technology is the object of a patent application filed by Promethera Biosciences. There are various benefits with this new technology; Promethera Biosciences cell-based models are derived from healthy human livers and acquire a metabolic capacity within the range of primary hepatocytes. They have long-term stability in culture as well as potential for large-scale production and reproducibility across batches. 

EMD Millipore’s ‘Pearl’ microfluidic technology maintains hepatocyte functionality by mimicking the liver microenvironment. When liver cells are cultured in the ‘Pearl’ format they recover key metabolic functions and could display phenotypic profiles of the intact organ for over a month. 

The project for developing a new product combining the strengths of EMD Millipore 'Pearl' microfluidic technology and of Promethera Biosciences H2Screen/H3Screen cells has been selected by the Belgian Walloon Region Biocluster (BioWin) and the Massachusetts Life Sciences Center (MLSC). It will be funded 900K€ in total for both partners. 

The Belgian Walloon region and the Massachusetts Life Sciences Center (MLSC) are partners in the International Collaborative Industry Program (ICIP). The program’s objective is to promote and motivate collaboration between life sciences companies in Massachusetts (USA) and other countries by facilitating partnerships, supporting exciting new projects, and providing joint funding for helping to swiftly design and develop innovative products and services. 

In April 2013 a call was launched with four partner foreign regions of the Massachusetts Life Sciences Center in the ICIP program. Promethera Biosciences and EMD Millipore were one of the four collaborative projects selected by independent Belgian and American panels of experts. 

”We are very pleased to initiate this collaboration with EMD Millipore and to combine our expertise to develop a ready to use liver based assay. We sincerely thank the Walloon region and the MLSC for funding this innovative project”, said Eric Halioua, Chief Executive Officer of Promethera Biosciences. 

“The opportunity to work closely with Promethera over the course of the project, speaks to the nature of our organization: enabling our partners to conduct potentially life-saving research,” says Robert Yates, President and CEO of EMD Millipore. “We are looking forward to building our relationship and more importantly to the outcomes this partnership has the potential to deliver. A sincere thanks to the MLSC for the opportunity to see what this collaboration can achieve and more importantly the continued support of the Massachusetts Life Sciences industry.” 

An urgent need for reliable human liver-based assays for early preclinical testing 
Early availability of reliable human liver-based assays is critical to the pharmaceutical industry in deciding to bring a lead compound in clinical phase development. 30% of drug candidates fail during clinical development due to toxicity issues. Hepatocyte (liver cells) based studies represent 85% of in vitro toxicology assays. But current models are limited by key technological challenges such as long-term stability of hepatic functionality to allow chronic toxicity testing, and obtaining a stable and consistent human cell source at acceptable cost. 


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Lab-on-a-Chip for Detecting Glucose
By integrating microfluidic chips with fiber optic biosensors, researchers in China are creating ultrasensitive lab-on-a-chip devices to detect glucose levels.
Soy Shows Promise as Natural Anti-Microbial Agent
Soy isoflavones and peptides may inhibit the growth of microbial pathogens that cause food-borne illnesses, according to a new study from University of Guelph researchers.
Soy Shows Promise as Natural Anti-Microbial Agent
Researchers from University of Guelph show that soy isoflavones and peptides could be used to reduce microbial contamination of food.
Parsortix Demonstrates Benefits Over Marker-Based Systems
Research published online in the International Journal of Cancer, shows the ParsortixTM System efficiently captures and harvests intact, viable circulating tumour cells (CTCs), including EpCAM-negative CTCs, to allow for broader downstream CTC analysis.
Experimental Therapy For Brain Cancer Could Prevent Drug Resistance
Information from penny-sized microfluidic chips allowed researchers to anticipate resistance to cancer treatment.
3D Printing of Lego Fluidics
Study shows how 3D printing can open up microfluidic technology to a wider audience.
New Method to Preserve Device to Monitor HIV Treatment
Inspired by pregnancy tests, scientists have developed a method to store microfluidic devices for months without refrigeration, giving developing countries an inexpensive and reliable way to treat patients.
Migration Creates Cancer Cell Vulnerabilities
Scientists found that migration can damage cancer cells’ nuclei and DNA, requiring repairs for their survival. The results may open new avenues for targeting metastatic cancer.
Scroll Up
Scroll Down
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!